P
ABBV icon

&Partners’s AbbVie ABBV Stock Holding History

&Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$107M Buy
425,683
+28,759
+7% +$6.19M 0.44% 40
2026
Q1 		$86.3M Buy
396,924
+14,444
+4% +$3.2M 0.43% 42
2025
Q4 		$87.4M Buy
382,480
+76,006
+25% +$17.3M 0.46% 38
2025
Q3 		$66.4M Buy
306,474
+22,265
+8% +$4.53M 0.43% 43
2025
Q2 		$52.7M Buy
284,209
+50,731
+22% +$9.43M 0.4% 48
2025
Q1 		$47.9M Buy
233,478
+24,746
+12% +$4.81M 0.51% 41
2024
Q4 		$37.8M Buy
208,732
+89,331
+75% +$16.4M 0.45% 46
2024
Q3 		$23.5M Buy
119,401
+80,443
+206% +$15M 0.45% 50
2024
Q2 		$6.68M Buy
38,958
+24,170
+163% +$4M 0.29% 83
2024
Q1 		$2.69M Buy
14,788
+6,544
+79% +$1.13M 0.37% 53
2023
Q4 		$1.28M Buy
8,244
+2,557
+45% +$373K 0.31% 76
2023
Q3 		$848K Buy
5,687
+66
+1% +$9.69K 0.4% 48
2023
Q2 		$757K Buy
5,621
+388
+7% +$56.9K 0.34% 60
2023
Q1 		$834K Sell
5,233
-122
-2% -$18.7K 0.4% 50
2022
Q4 		$865K Sell
5,355
-44
-0.8% -$6.75K 0.43% 50
2022
Q3 		$725K Sell
5,399
-130
-2% -$18.7K 0.42% 56
2022
Q2 		$847K Buy
5,529
+99
+2% +$15.1K 0.49% 44
2022
Q1 		$880K Buy
5,430
+2,207
+68% +$321K 0.49% 45
2021
Q4 		$436K Sell
3,223
-475
-13% -$56.1K 0.26% 91
2021
Q3 		$399K Buy
3,698
+200
+6% +$22.9K 0.25% 90
2021
Q2 		$428K Buy
3,498
+745
+27% +$83.9K 0.28% 81
2021
Q1 		$298K Sell
2,753
-100
-4% -$10.7K 0.22% 107
2020
Q4 		$306K Hold
2,853
– – 0.26% 95
2020
Q3 		$250K Buy
2,853
+500
+21% +$47.1K 0.25% 93
2020
Q2 		$231K Buy
+2,353
New +$207K 0.28% 95
2020
Q1 		– Sell
-2,335
Closed -$207K – 145
2019
Q4 		$207K Buy
+2,335
New +$194K 0.25% 137

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

&Partners's ABBV Position: Q2 2026 in Review

&Partners increased its AbbVie (ABBV) stake by 7.2% in Q2 2026, buying an estimated $6.19M and bringing the position to 425,683 shares worth $107M. The position accounts for 0.44% of the portfolio, ranked #40.

&Partners first reported a position in ABBV in Q4 2019 and has held it in 26 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • &Partners held 425,683 shares of AbbVie worth $107M as of Q2 2026.
  • &Partners bought 28,759 AbbVie shares in Q2 2026, an estimated $6.19M.
  • AbbVie made up 0.44% of &Partners's portfolio in Q2 2026, its #40 holding.
  • &Partners first reported a position in AbbVie in Q4 2019 and has held it in 26 quarters since.
  • 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.